Literature DB >> 18755200

Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment.

Sharon L Hale1, Wangde Dai, Joan S Dow, Robert A Kloner.   

Abstract

AIMS: Ideally, mesenchymal stem cells (MSC) home to and/or remain at the site of damaged myocardium when administered after myocardial infarction. However, MSC may not remain in the heart, but instead relocate to other areas. We investigated quantitatively the distribution of labeled rat MSC, given by two routes after coronary artery occlusion/reperfusion in rats. MAIN
METHODS: Rats were subjected to 45 min of coronary artery occlusion and 7 days of reperfusion. Before reperfusion rats received 2 x 10(6) MSC, labeled with europium, injected directly into the ischemic region of the heart (n = 9) or intravenously (n = 8). After 1 week tissues were analyzed for label content together with a standard curve of known quantities of labeled MSC. KEY
FINDINGS: In rats receiving cells injected directly into the myocardium, 15% of labeled cells were retained in the heart. When the cells were administered intravenously, no MSC were detected in the heart. The route of administration did not affect distribution to other organs, as the number of MSC in liver, spleen and lung was similar with both routes of delivery. SIGNIFICANCE: Even with direct intramyocardial injection, only a small proportion of the cells are retained in the heart, instead traveling to other organs. With intravenous injection there was no evidence that cells "homed" to the damaged heart. Although cell delivery to the heart was significantly affected by the route of administration, the distribution of cells to other organs was similar with both routes of administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18755200      PMCID: PMC2582905          DOI: 10.1016/j.lfs.2008.07.020

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  23 in total

1.  Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells.

Authors:  Jonathan M Hill; Alexander J Dick; Venkatesh K Raman; Richard B Thompson; Zu-Xi Yu; K Allison Hinds; Breno S S Pessanha; Michael A Guttman; Timothy R Varney; Bradley J Martin; Cynthia E Dunbar; Elliot R McVeigh; Robert J Lederman
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

2.  Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia.

Authors:  A Kawamoto; H C Gwon; H Iwaguro; J I Yamaguchi; S Uchida; H Masuda; M Silver; H Ma; M Kearney; J M Isner; T Asahara
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

3.  Rebuilding a damaged heart: long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function.

Authors:  Jochen Müller-Ehmsen; Kirk L Peterson; Larry Kedes; Peter Whittaker; Joan S Dow; Tiffany I Long; Peter W Laird; Robert A Kloner
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

4.  Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart.

Authors:  Catalin Toma; Mark F Pittenger; Kevin S Cahill; Barry J Byrne; Paul D Kessler
Journal:  Circulation       Date:  2002-01-01       Impact factor: 29.690

5.  111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction.

Authors:  B B Chin; Y Nakamoto; J W M Bulte; M F Pittenger; R Wahl; D L Kraitchman
Journal:  Nucl Med Commun       Date:  2003-11       Impact factor: 1.690

6.  Long-term outcome of fetal cell transplantation on postinfarction ventricular remodeling and function.

Authors:  Mu Yao; Thomas Dieterle; Sharon L Hale; Joan S Dow; Laurence H Kedes; Kirk L Peterson; Robert A Kloner
Journal:  J Mol Cell Cardiol       Date:  2003-06       Impact factor: 5.000

7.  Magnetic resonance imaging overestimates ferumoxide-labeled stem cell survival after transplantation in the heart.

Authors:  John Terrovitis; Matthias Stuber; Amr Youssef; Steve Preece; Michelle Leppo; Eddy Kizana; Michael Schär; Gary Gerstenblith; Robert G Weiss; Eduardo Marbán; M Roselle Abraham
Journal:  Circulation       Date:  2008-03-10       Impact factor: 29.690

8.  Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts.

Authors:  Charles E Murry; Mark H Soonpaa; Hans Reinecke; Hidehiro Nakajima; Hisako O Nakajima; Michael Rubart; Kishore B S Pasumarthi; Jitka Ismail Virag; Stephen H Bartelmez; Veronica Poppa; Gillian Bradford; Joshua D Dowell; David A Williams; Loren J Field
Journal:  Nature       Date:  2004-03-21       Impact factor: 49.962

Review 9.  Skeletal myoblast transplantation for cardiac repair.

Authors:  Philippe Menasché
Journal:  Expert Rev Cardiovasc Ther       Date:  2004-01

10.  Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution.

Authors:  Israel M Barbash; Pierre Chouraqui; Jack Baron; Micha S Feinberg; Sharon Etzion; Ariel Tessone; Liron Miller; Esther Guetta; Dov Zipori; Laurence H Kedes; Robert A Kloner; Jonathan Leor
Journal:  Circulation       Date:  2003-08-04       Impact factor: 29.690

View more
  21 in total

Review 1.  Emerging therapeutic approaches for multipotent mesenchymal stromal cells.

Authors:  Paolo F Caimi; Jane Reese; Zhenghong Lee; Hillard M Lazarus
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

Review 2.  Arrhythmia in stem cell transplantation.

Authors:  Shone O Almeida; Rhys J Skelton; Sasikanth Adigopula; Reza Ardehali
Journal:  Card Electrophysiol Clin       Date:  2015-04-09

Review 3.  Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells.

Authors:  Andrey A Karpov; Daria V Udalova; Michael G Pliss; Michael M Galagudza
Journal:  Cell Prolif       Date:  2016-11-23       Impact factor: 6.831

Review 4.  Mesenchymal stem cell delivery routes and fate.

Authors:  Andreas Kurtz
Journal:  Int J Stem Cells       Date:  2008-11       Impact factor: 2.500

Review 5.  The role of nanomaterials in cell delivery systems.

Authors:  Ali Golchin; Simzar Hosseinzadeh; Leila Roshangar
Journal:  Med Mol Morphol       Date:  2017-11-23       Impact factor: 2.309

Review 6.  Intra-myocardial biomaterial injection therapy in the treatment of heart failure: Materials, outcomes and challenges.

Authors:  Devin M Nelson; Zuwei Ma; Kazuro L Fujimoto; Ryotaro Hashizume; William R Wagner
Journal:  Acta Biomater       Date:  2010-07-07       Impact factor: 8.947

7.  Optimized delivery system achieves enhanced endomyocardial stem cell retention.

Authors:  Atta Behfar; Jean-Pierre Latere; Jozef Bartunek; Christian Homsy; Dorothee Daro; Ruben J Crespo-Diaz; Paul G Stalboerger; Valerie Steenwinckel; Aymeric Seron; Margaret M Redfield; Andre Terzic
Journal:  Circ Cardiovasc Interv       Date:  2013-12-10       Impact factor: 6.546

8.  Donor mesenchymal stromal cells (MSCs) undergo variable cardiac reprogramming in vivo and predominantly co-express cardiac and stromal determinants after experimental acute myocardial infarction.

Authors:  Gustavo Yannarelli; James N Tsoporis; Jean-Francois Desjardins; Xing Hua Wang; Ali Pourdjabbar; Sowmya Viswanathan; Thomas G Parker; Armand Keating
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

9.  Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor.

Authors:  Svetlana Komarova; Justin Roth; Ronald Alvarez; David T Curiel; Larisa Pereboeva
Journal:  J Ovarian Res       Date:  2010-05-25       Impact factor: 4.234

10.  Electrospun nanofibrous sheets of collagen/elastin/polycaprolactone improve cardiac repair after myocardial infarction.

Authors:  Yang Liu; Yachen Xu; Zhenhua Wang; Dezhong Wen; Wentian Zhang; Sebastian Schmull; Haiyan Li; Yao Chen; Song Xue
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.